GREEN CROSS MEDICAL SCIENCE CORPORATION Green Cross Medical Science Corporation Share Price
Equities
A142280
KR7142280007
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,100 KRW | +0.86% |
|
+1.11% | -14.05% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 113B 83.47M 6.96B | Sales 2023 | 94.01B 69.38M 5.79B | Capitalization | 101B 74.22M 6.19B |
|---|---|---|---|---|---|
| Net income 2022 | -3.58B -2.64M -220M | Net income 2023 | 1.8B 1.33M 111M | EV / Sales 2022 | 1.19 x |
| Net Debt 2022 | 12.65B 9.34M 779M | Net Debt 2023 | 16.84B 12.42M 1.04B | EV / Sales 2023 | 1.25 x |
| P/E ratio 2022 |
-34
x | P/E ratio 2023 |
62.8
x | Employees | 131 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 46.71% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.86% | ||
| 1 week | +1.11% | ||
| Current month | +0.74% | ||
| 1 month | -0.36% | ||
| 3 months | -9.99% | ||
| 6 months | +5.94% | ||
| Current year | -14.05% |
1 week
4 020.00
4 120.00
1 month
3 940.004 150.00
Current year
3 940.004 960.00
1 year
3 490.005 880.00
3 years
3 490.0013 350.00
5 years
2 785.0019 950.00
10 years
2 785.0030 800.00
| Managers | Title | Age | Since |
|---|---|---|---|
Yu-Shin Kim
BRD | Director/Board Member | 59 | - |
Sang-Soon Hwang
AUD | Comptroller/Controller/Auditor | 70 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jeong-Han Song
BRD | Director/Board Member | 61 | 27/19/27 |
Yu-Shin Kim
BRD | Director/Board Member | 59 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/24/03 | 4,100 | +0.86% | 23,043 |
| 02/24/02 | 4,065 | -0.12% | 13,125 |
| 30/24/30 | 4,070 | -0.25% | 8,854 |
| 29/24/29 | 4,080 | +0.62% | 17,732 |
End-of-day quote Korea S.E., May 03, 2024
More quotes
Green Cross Medical Science Corporation is a Korea-based company principally engaged in the medical business. The Company mainly operates its business through three segments: diagnosis reagent segment, blood bag segment and blood dialysate segment. Its diagnosis reagent segment provides in vitro diagnosis reagents and medical equipment. Its blood bag segment provides filter bags and blood bags. The Company distributes its products within domestic market and to overseas markets.
Calendar
13/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -14.05% | 63.86M | |
| -1.89% | 12.56B | |
| -9.59% | 7.68B | |
| -1.31% | 5.29B | |
| +21.82% | 5.24B | |
| +0.02% | 4.57B | |
| -50.89% | 3.29B | |
| +6.42% | 2.6B | |
| -10.02% | 2.2B | |
| -8.29% | 1.79B |
- Stock Market
- Equities
- A142280 Stock